| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Wednesday, June 19, 2019 Allergan's share prices have significantly fallen from their high in 2015, but now the company is ready to make a big move in response to its struggles, one analyst writes. |
|
|
Top Stories Of The Week Monday, June 17, 2019 Using corporate financial statements and annual earnings transcripts, FiercePharma has put together its list of the top 20 drugs by 2018 U.S. sales. Tuesday, June 18, 2019 Sanofi is quitting two more programs it picked up in a 2015 pact with Voyager—a gene therapy for Huntington’s disease and one for Friedreich’s ataxia. Thursday, June 20, 2019 Sanofi is cutting 466 jobs in France and Germany as part of the reorganization of its R&D group. The job losses are part of a pivot away from cardiovascular diseases and toward immuno-oncology drugs and gene therapies. Wednesday, June 19, 2019 It was less than a year ago that Merck’s board scrapped a policy requiring CEOs to retire at the age of 65 in a move designed to keep Ken Frazier around. Now, the company is scouting replacements for the long-tenured helmsman, reports say. Friday, June 14, 2019 After its nearly $2 billion buyout by oncology giant Roche last winter, Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data. Wednesday, June 19, 2019 Bluebird Bio, which this month got conditional European approval for its first gene therapy, says the launch will not occur until 2020 because regulators required it to "tighten up" its manufacturing before treating its first commercial patient. Monday, June 17, 2019 A University of Pennsylvania team has discovered a protein that helps determine the fate of exhausted T cells—and that might be able to be targeted to improve immuno-oncology treatments. Monday, June 17, 2019 CANNES, FRANCE—GlaxoSmithKline and its agency McCann Health broke the dry spell for pharma winners at Lions Health, picking up the first Grand Prix since 2016. The winning entry? A smartphone app that measures lung capacity, released in China. Monday, June 17, 2019 Barely two years after forking over $263 million up front for the ex-Asia rights to BeiGene’s PD-1 drug, Celgene is bowing out—and paying a $150 million termination fee to do it. Friday, June 14, 2019 For Sanofi, snapping up Biogen spinout Bioverativ for $11.6 billion bolstered its rare disease franchise. But for a Swiss man, an early whiff of the deal has allegedly brought some illegal gains—and now, a civil and a criminal case in the U.S. Who's the Sanofi EVP who may have tipped him off? Resources Sponsored by: Elemental Machines How can the Internet of Things (IoT) enable you to meet GxP? Sponsored by: Veradigm Patients living with diabetes deserve better – Real-World Evidence for effecting/realizing change in the management of type 2 diabetes and cardiovascular/renal comorbidities. Sponsored by: AlphaSense What is agile competitive intelligence, and how can it help take market research to the next level? Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. |
